RxDoctor Payments Data

Bhupesh Khadka, MD

Nephrology · Cincinnati, OHNPI 1629297551

Payments from drug & device makers

$459in general payments, 2019–2025

Across 18 payments — averaging $25.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nxstage Medical, Inc.$121
  • Bayer$62
  • Novartis$58
  • Boehringer Ingelheim$45
  • Vifor Pharma, Inc.$43
  • Calliditas Therapeutics US Inc.$39
  • plus $92 from 4 others

What the payments were for

  • Food & beverage$459100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$459 in reported general payments places this provider in the 30th percentile of 450 nephrology providers in Ohio.

See all nephrology providers in Ohio

Medicare billing

Part B allowed, 2024
$145,787
Medicare patients
414
Services billed
1,335

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin61$48,692
FarxigaDapagliflozin Propanediol43$43,097
LokelmaSodium Zirconium Cyclosilicate48$21,418
Cinacalcet Hcl26$5,881
Sevelamer Carbonate26$5,602
Calcium Acetate21$2,116
Torsemide90$1,197
Hydralazine Hcl88$1,147
Losartan Potassium186$1,144
Doxazosin Mesylate72$1,108
Tamsulosin Hcl153$1,074
Nifedipine ErNifedipine27$857
Allopurinol134$846
Potassium Citrate ErPotassium Citrate21$816
Metoprolol Succinate47$806

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$45$48,69261 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 450 nephrology providers in Ohio.

Other nephrology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →